Chromocell Therapeutics Bolsa (AMEX: CHRO)

Últimas noticias sobre Chromocell Therapeutics (AMEX:CHRO) Bolsa

Chromocell Therapeutics

Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.

Chromocell Therapeutics Corporation Common Stock

Chromocell Therapeutics Corp

CHROMOCURE INC by Chromocure, Inc.

ChromaDex Corp

Chromia - United States Dollar

Chronicle

Chrono.tech - United States Dollar

<ul>
<li>Muñoz to lead Hyundai Motor Company's global business</li>
<li>Continues to serve on the Hyundai Motor Company Board of Directors</li>
</ul>
Hyundai Motor Company (HMC) today announced the appointment of José Muñoz as the company's President and CEO, effective Jan. 1, 2025. Muñoz will lead Hyundai Motor Company's global business, succeeding current President and CEO Jaehoon Chang, who has been promoted to the Vice Chair of Hyundai Motor Group – Automotive Division.

News

Management

HYMLF

HYMTF

Reported Earlier, Hyundai Motor Company Names José Muñoz As President And Chief Executive Officer, Effective January 1, 2025

Macro Economic Events

Econ #s

Economics

France Harmonised Index of Consumer Prices (MoM) For October 0.3% Vs. 0.3% Est.; -1.3% Prior

France Consumer Price Index (MoM) For October 0.3% Vs. 0.2% Est.; -1.3% Prior

OneStream, Inc announced today the pricing of the previously announced underwritten public offering of 15,000,000 shares of its Class&nbsp;A common stock, at a public offering price of $31.00 per share, of which 9,006,948 shares will be sold by selling stockholders and 5,993,052 shares will be sold by OneStream as part of a non-dilutive "synthetic secondary" transaction (the "Synthetic Secondary").

Reported Earlier, OneStream Prices Secondary Offering Of 15M Class A Common Stock At $31/Share

Associated expects to use the net proceeds from this offering for general corporate purposes to support continued organic growth and capital generation, which may include investments in Associated Bank, N.A. and potential balance sheet optimization strategies.

Reported Earlier, Associated Banc-Corp Prices $300M Public Offering Of 12M Common Stock Offering At $25/Share

In a unique perspective, a cryptocurrency analyst equated Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to gunpowder, arguing that sooner or later sovereign nations would be compelled to adopt the leading cryptocurrency.
What Happened: Matt Huang, CEO of cryptocurrency-focused investment firm Paradigm, penned a blog post Thursday, highlighting Bitcoin&#8217;s growing prominence. 
Huang argued that like gunpowder became indispensable after its discovery, the same would eventually pan out for emerging technologies like artificial intelligence, drones, and Bitcoin.
&#8220;Sovereigns can no longer afford to dismiss BTC. From a game theoretic perspective, BTC is like gunpowder, not the iPhone. Christopher,&#8221; the analyst remarked.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin for the Sovereign <a href="https://t.co/HD1UpcD6J7">pic.twitter.com/HD1UpcD6J7</a>
&mdash; Matt Huang (@matthuang) <a href="https://twitter.com/matthuang/status/1857127295145902586?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Huang highlighted how calls for the establishment of a Bitcoin strategic reserve have intensified since Donald Trump&#8217;s presidential victory, suggesting the opening of the Overton window for Bitcoin acceptance in America.
&#8220;Sovereigns that build BTC reserves early will benefit from significantly better entry prices. The race to build BTC reserves is on.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41912787/buckle-up-for-the-bull-markets-most-fun-phase-says-industry-expert-bitcoin-ethereum-dogecoin-about-to-enter-the-euphoria-stage?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Buckle Up&#8217; For The Bull Market&#8217;s &#8216;Most Fun Phase,&#8217; Says Industry Expert: Bitcoin, Ethereum, Dogecoin Abo</a>
Why It Matters: The Republican side vigorously promoted the idea of a Bitcoin reserve leading up to the elections, with none other than President-elect Trump <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40001426/trump-aims-to-make-us-crypto-capital-of-the-planet-well-get-it-done">vowing to establish one</a> if voted to power.
A few days later, Senator Cynthia Lummis (R-Wyo.) <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40087880/cynthia-lummis-unveils-strategic-bitcoin-reserve-legislation-this-is-our-louisiana-purchas">proposed </a>a bill, called the BITCOIN Act, aimed at creating a strategic Bitcoin stockpile to support America's balance sheet.
The senator reiterated her pledge following the Republican Party&#8217;s electoral triumph last week, as Polymarket odds showed a <a href="https://polymarket.com/event/will-trump-create-a-national-bitcoin-reserve-in-his-first-100-days?tid=1731494882651">35%</a> probability of this happening.
Moreover, emboldened by broader support, Pennsylvania introduced the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41986427/pennsylvania-introduces-bitcoin-strategic-reserve-act-to-invest-up-to-700-million-in-btc">Bitcoin Strategic Reserve Act</a>, hoping to build its own state-held Bitcoin reserve.
Price Action: At the time of writing, Bitcoin was trading at $87,824.55, down 2.35% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41998869/analyst-says-bitcoin-lives-rent-free-in-peoples-minds-after-peter-schiffs-cheeky-social-security-trust-remark">Peter Schiff&#8217;s Cheeky Bitcoin Turnaround Post Earns Reaction From Popular Analyst: &#8216;You Buy It And Become Rich Or You Keep Hating And Turn Crazy&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

Bitcoin Is Like Gunpowder And That Is Why Sovereign States Can't Refuse Its Adoption, Says Crypto Analyst

Buybacks

SNDL

Reported Earlier, SNDL Extends Share Repurchase Program With C$100M Authorization, Aiming To Repurchase Up To 13.2M Shares

Equus Total Return, Inc. (NYSE:<a href="https://www.benzinga.com/stock/EQS#NYSE">EQS</a>) ("Equus" or the "Company") reports net assets as of September 30, 2024, of $40.2 million. Net asset value per share decreased to $2.96 as of September 30, 2024, from $3.66 as of June 30, 2024. Comparative data is summarized below (in thousands, except per share amounts):&nbsp;&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>As of the Quarter Ended</td>
<td>9/30/2024</td>
<td>6/30/2024</td>
<td>3/31/2024</td>
<td>12/31/2023</td>
<td>9/30/2023 &nbsp;</td>
</tr>
<tr>
<td>Net assets</td>
<td>$40,165</td>
<td>$49,792</td>
<td>$45,892</td>
<td>$48,287</td>
<td>$47,128</td>
</tr>
<tr>
<td>Shares outstanding</td>
<td>13,586</td>
<td>13,586</td>
<td>13,586</td>
<td>13,586</td>
<td>13,518</td>
</tr>
<tr>
<td>Net assets per share</td>
<td>$2.96</td>
<td>$3.66</td>
<td>$3.38</td>
<td>$3.55</td>
<td>$3.49</td>
</tr>
</tbody>
</table>
</figure>

Reported Earlier, Equus Total Return Reports Net Assets As Of September 30, 2024, Of $40.2M; Net Asset Value Per Share $2.96

ZLAB

Reported Earlier, Zai Lab Prices 7.8M American Depositary Shares At $25.50/ADS In $200M Public Offering

Maui Land &amp; Pineapple Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLP#NYSE">MLP</a>) reported quarterly losses of $(0.07) per share. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported $3.02 million in sales this quarter. This is a 43.98 percent increase over sales of $2.10 million the same period last year.

Earnings

Maui Land & Pineapple Co Q3 EPS $(0.07) Down From $(0.06) YoY, Sales $3.02M Up From $2.10M YoY

GreenPower Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GP#NASDAQ">GP</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $5.347 million which missed the analyst consensus estimate of $7.967 million by 32.88 percent. This is a 36.35 percent decrease over sales of $8.400 million the same period last year.

Earnings Misses

GreenPower Motor Co Q2 2025 GAAP EPS $(0.18) Misses $(0.16) Estimate, Sales $5.347M Miss $7.967M Estimate

Beam Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.12) by 175 percent. The company reported quarterly sales of $11.482 million which missed the analyst consensus estimate of $18.863 million by 39.13 percent. This is a 30.35 percent decrease over sales of $16.486 million the same period last year.

Earnings Beats

BEEM

Beam Global Q3 2024 GAAP EPS $0.09 Beats $(0.12) Estimate, Sales $11.482M Miss $18.863M Estimate

Lantmännen will invest more than 100 million euros in a state-of–the-art <a href="https://www.globenewswire.com/Tracker?data=D-7Y-KVbP6QZknfadXEZ-FyiOL801tmcb6MoPLIt1GBtRzzMxYqB5y0WMAfkDOuP8wF9RdBMPWvDS7IIKC_OkWudCUCt9vi-8ARGYU9fdadf5aFadydlfMoC2c0oEek0wq9shl6f0tFxH4iEsBbG2plhHfhgHB7WME97-NbSZIM6dfFRmaj3AkU_gZXrXeRD6wSfFlbL5NZEKQdFWd05Ix8BUt1dMN_MHpAiD0GLnSSve8knOhEkT3alPDLqD0Z4qqemEbKkxRZ3MJ3oKFuKXBYY26VDZ92n-tTgubAPhQo=">factory in Sweden</a>, while partnering with Ingredion to develop a differentiated portfolio of plant-based protein isolates based on yellow peas. Construction of the production plant will be completed in 2027.

INGR

Reported Earlier, Ingredion And Lantmännen Forge Strategic Alliance To Boost European Plant-Based Protein Market, Invest Over €100M In New Pea Protein Facility

U.K. Trade Balance Non-EU For September -5.31B Vs. -4.85B (Revised) Prior

U.K. Trade Balance For September -16.32B Vs. -15.70B Est.; -15.21B (Revised) Prior

U.K. Monthly Gross Domestic Product (GDP) 3M/3M Change For September 0.1% Vs. 0.2% Est.; 0.2% Prior

U.K. Manufacturing Production (MoM) For September -1.0% Vs. 0.0% Est.; 1.3% (Revised) Prior

U.K. Industrial Production (MoM) For September -0.5% Vs. 0.1% Est.; 0.5% Prior

U.K. Gross Domestic Product (QoQ) Preliminary For Q3 0.1% Vs. 0.2% Est.; 0.5% Prior

U.K. Gross Domestic Product (YoY) Preliminary For Q3 1.0% Vs. 0.1% Est.; 0.7% Prior

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!



Moving stocks this morning are earnings reports, acquisition plans, new drug data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>INVO Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is rocketing more than 55% alongside its <a href="https://finance.yahoo.com/news/invo-reports-fourth-quarter-full-205900118.html">Q4 earnings report</a>.</li>



<li>Vanda Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/vnda-stock-quote/">VNDA</a>) shares are soaring over 38% on <a href="https://www.nasdaq.com/press-release/future-pak-confirms-proposal-to-acquire-vanda-pharmaceuticals-for-%247.25-to-%247.75-per">a firm acquisition proposal</a>.</li>



<li>VIA Optronics (NYSE:<a href="https://investorplace.com/stock-quotes/viao-stock-quote/">VIAO</a>) stock is surging more than 32% with heavy pre-market trading.</li>



<li>Clene (NASDAQ:<a href="https://investorplace.com/stock-quotes/clnn-stock-quote/">CLNN</a>) shares are rising over 26% on <a href="https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain%7Csection%3Aon-the-move">new drug data</a>.</li>



<li>Chromocell Therapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/chro-stock-quote/">CHRO</a>) stock is gaining more than 26% on an update to a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239123&amp;type=PDF&amp;symbol=CHRO&amp;cdn=722216dc7f57070dff83767fe9648f9d&amp;companyName=Chromocell+Therapeutics+Corporation&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-04-17">secondary stock offering</a>.</li>



<li>CXApp (NASDAQ:<a href="https://investorplace.com/stock-quotes/cxai-stock-quote/">CXAI</a>) shares are increasing over 26% with its <a href="https://www.marketwatch.com/story/cxapp-shares-rise-29-on-4q-2023-annual-recurring-revenue-growth-13f8abea">latest earnings report</a>.</li>



<li>Seelos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/seel-stock-quote/">SEEL</a>) stock is climbing more than 24% without any clear news on Wednesday morning.</li>



<li>Mobile Global Esports (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgam-stock-quote/">MGAM</a>) shares are getting a 22% boost as it <a href="https://investorplace.com/2024/04/why-is-mobile-global-esports-mgam-stock-down-18-today/">prepares for delisting</a>.</li>



<li>Gamer Pakistan (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/">GPAK</a>) stock is jumping 21% despite a lack of news today.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) shares are up over 19% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238318&amp;type=PDF&amp;symbol=GRTX&amp;cdn=6788b7c94daccbdc9a6c5412e270d44c&amp;companyName=Galera+Therapeutics+Inc.&amp;formType=SC+13G&amp;formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-04-16">shareholder stake update</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Trilogy Metals (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tmq-stock-quote/">TMQ</a>) stock is plummeting more than 22% <a href="https://www.nasdaq.com/press-release/trilogy-metals-provides-update-on-the-ambler-access-project-2024-04-17">following an update</a> to its Ambler Access Project.</li>



<li>Trio Petroleum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tpet-stock-quote/">TPET</a>) shares are diving over 20% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239194&amp;type=PDF&amp;symbol=TPET&amp;cdn=fb7a5495a316777660288b1087458323&amp;companyName=Trio+Petroleum+Corp.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-17">securing senior notes and a purchase agreement</a>.</li>



<li>Connexa Sports Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/yyai-stock-quote/">YYAI</a>) stock is tumbling more than 18% on Wednesday morning.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) shares are taking a close to 18% beating following a rally yesterday.</li>



<li>Ontrak (NASDAQ:<a href="https://investorplace.com/stock-quotes/otrk-stock-quote/">OTRK</a>) stock is sliding over 16% with the release of its <a href="https://finance.yahoo.com/news/ontrak-announces-2023-fourth-quarter-200500612.html">Q4 2023 earnings report</a>.</li>



<li>Dragonfly Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/dfli-stock-quote/">DFLI</a>) shares are retreating more than 16% <a href="https://investorplace.com/2024/04/why-is-dragonfly-energy-dfli-stock-up-56-today/">after rallying yesterday</a>.</li>



<li>Dynatronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/">DYNT</a>) stock is pulling back over 16% <a href="https://investorplace.com/2024/04/why-is-dynatronics-dynt-stock-up-93-today/">after rising on Tuesday</a>.</li>



<li>Ryvyl (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvyl-stock-quote/">RVYL</a>) shares are still falling more than 15% despite <a href="https://www.nasdaq.com/press-release/ryvyl-inc.-announces-cancellation-of-proposed-underwritten-public-offering-2024-04-16">canceling a proposed public offering</a>.</li>



<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) stock is dropping over 14% <a href="https://investorplace.com/2024/04/why-is-hub-cyber-security-hubc-stock-up-35-today/">after a rally yesterday</a>.</li>



<li>iSun (NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/">ISUN</a>) shares close out our pre-market stock movers down more than 13% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238741&amp;type=PDF&amp;symbol=ISUN&amp;cdn=82f25393dbc89b776256155c3f0856b7&amp;companyName=iSun+Inc.&amp;formType=10-K&amp;formDescription=Annual+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-16">on an investor update</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-april-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

SBFM, BPTH and INDO among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chromocell Therapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/chro-stock-quote/">CHRO</a>) just reported results for the first quarter of 2024.<ul><li>Chromocell Therapeutics reported earnings per share of -55 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/chro-stock-earnings-chromocell-therapeutics-for-q1-of-2024/">CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024

Chromocell Therapeutics Corp (CHRO) has provided an update. Chromocell Therapeutics Corporation has recently entered into financial agreements that...

Chromocell Therapeutics Strengthens Finances with Strategic Agreements

Chromocell announces stock repurchase plan

Wall Street Breakfast: The Week Ahead

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chromocell Therapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/chro-stock-quote/">CHRO</a>) just reported results for the second quarter of 2024.<ul><li>Chromocell Therapeutics reported earnings per share of -31 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/chro-stock-earnings-chromocell-therapeutics-for-q2-of-2024/">CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024

Chromocell Therapeutics (CHRO) board of directors has authorized an amendment to the Company's existing stock repurchase plan to increase the total...

Chromocell Therapeutics announces amendment to stock repurchase plan

Chromocell announces amendment to stock repurchase plan

Chromocell Therapeutics (CHRO) announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-...

Chromocell unveils injectable depot program for treating surgical pain

AMAT

ARDT

ARTV

BABA

BDTX

CHRO

CLNN

CSCO

CXAI

DFLI

DXYZ

DYNT

EDBL

GOLD

GPAK

GRTX

GTHX

HEPA

HUBC

INVO

ISUN

IVCA

MDIA

MGAM

MNDR

MNDY

NVFY

ONON

OTRK

PAAS

PINS

RVYL

RWOD

SAVA

SAVE

SEEL

SNAP

SPGC

TPET

TWFG

VIAO

VNDA

VZLA

YYAI

ZCMD

Biotech

Interview

General

This Biotech Is Innovating In Non-Opiod Solutions For Intense Pain

Health Care

Press Releases

Chromocell  Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

Chromocell Issues Letter to Stockholders from Chief Executive Officer

Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024

Chromocell to Participate in the Virtual Investor Lunch Break Series

Financing

Chromocell Announces Stock Repurchase Plan

Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Chromocell to Participate in Life Sciences Investor Forum September 19th

Chromocell Announces Amendment to Stock Repurchase Plan

Chromocell to Present at Upcoming Fall Investor Conferences

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain

Comments

Chromocell Therapeutics

Noticias

Últimas noticias sobre Chromocell Therapeutics (AMEX:CHRO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL